Synthesis, characterization, analgesic and anti-inflammatory activity of new pyrazole derivatives

Pullagura Priyadarsini,[a] Vallabhaneni Madhavarao,[a*] and Bodepudi Sudheer Chowdary [b]

[a] *Dept. of Chemistry, Bapatla Engineering College, Bapatla, Acharya Nagarjuna University, Guntur (District), Andhra Pradesh-522 101, India*
[b] *Dept. of Pharmacology, Bapatla College of Pharmacy, Jawaharlal Nehru Technical University-K, Bapatla, A.P., India*
*E-mail: vmrgpm@gmail.com*

Abstract

The synthesis of nine new pyrazole derivatives was achieved from β-hydroxy enones and hydrazines by using a trace of piperidine in methanol at room temperature. The use of piperidine provides more yield and purity of products in lesser time when compared to the other reagents. All synthetic compounds were characterized by their physical properties, NMR and LC mass spectral data. The pyrazole derivatives were screened for their analgesic and anti-inflammatory activities *in vivo*. The derivatives exhibited moderate to significant activities in comparison to control, and most of the pyrazoles were competent with standard drugs (Pentazocine and Indomethacin).

R^1 = Cl, NO$_2$, OCH$_3$, R^2= H, C$_6$H$_5$, 2,4-DNP

Keywords: Pyrazoles, β-hydroxy-enones, hydrazines, piperidine, anti-inflammatory activity, analgesic activity

Introduction

Pyrazoles are important heteroaromatic compounds with two nitrogen atoms in the five-membered ring system. They play a vital role in the pharmaceutical[1] and agrochemical industry.[2,3] They are classed as azoles.[4] Azoles occupy a domain of interest in natural and synthetic chemistry. Pyrazoles resemble benzene, and most of their properties were analyzed in comparison with the derivatives of benzene.[5] Knorr synthesized triaryl pyrazoles for the first time, by condensation of hydrazines with β-diketones.[6] Varma and co-workers developed a room temperature protocol for pyrazole synthesis using water as the solvent.[7] The binding of heterocyclic compounds with an acyclic sugar moiety, forming thus acyclic-nucleosides, has commanded worldwide attention of many research groups because of their high potential to exhibit chemotherapeutic activity.[8,9] Substituted pyrazole and its analogs have been used as precursors for the synthesis of various biologically active molecules.

The pyrazole nucleus is common in a number of biologically active molecules exhibiting antibacterial,[10,11] antitubercular,[12] anti-depressant,[13] anti-inflammatory,[14,15] analgesic,[16] anticancer,[17,18] antioxidant,[19,20] and other activities. The efficiency of microwave heating in dramatically reducing reaction times has recently been proven in several fields of organic chemistry.[21,22] There are numerous methods for synthesizing pyrazoles,[23-25] among which is the 1,3-dipolar cycloaddition of diazo compounds (as 1,3-dipoles) with alkenes,[23-26] or alkynes.[27-29] The utility of diazo compounds in such reactions remains to be explored in new domino reactions, the tandem 1,3-dipolar cycloaddition / intramolecular - aza-addition/ oxidative aromatization, which has led to an efficient construction of substituted analogs of withasomnines from readily available acyclic starting materials with diazomethanes under mild conditions in a single step.[30-32] There are still unexplored aspects of this area of research.

Results and Discussion

The importance and biological activities of pyrazoles led us to prepare new pyrazoles in three steps followed by a study of their analgesic and anti-inflammatory activities *in vivo*. The synthetic process initially involved condensation of cinnamic acids[33] with *o*-hydroxy-4'-acetoxyacetophenones in pyridine using $POCl_3$ as a condensing agent, to obtain 2'-cinnamoyloxyacetophenones (**5-7**). These were treated with powdered KOH in pyridine to give β-hydroxy-enones,[34,35] and then converted into pyrazoles by treating with alkaline hydrazine. The procedure for the preparation of the desired pyrazoles **11-19** is given in Scheme 1.

The optimization of the reaction conditions was carried out with β-hydroxy-enones as model substrate using different bases and solvents, at room temperature (Table 1). The best results were attained when the reaction was run at room temperature with methanol as a solvent in the presence of piperidine in a catalytic amount, providing the new pyrazoles (**11**-**19**). Piperidine proved to be very effective in increasing the yields as well as the purity of the products within considerably less time than the other reagents. The completion of the reaction and purity of the products were monitored by thin-layer chromatography. Pinto et.al[36] has reported some pyrazoles which were prepared from 2-styrylchromones under reflux conditions in methanol.

All the final products were confirmed from their spectral data, *viz.* ^{1}H and ^{13}C-NMR, LC-Mass. Signals in PMR at δ 6.54 - 7.15 (1H, s) indicate H(4) in pyrazole ring. The δ value at 7.27-7.90 was due to shielding of α-protons in the styryl group, whereas β-protons resonate at relatively higher δ values because of polarization of π-electrons, in the range 7.40-7.93 ppm. The *trans* configuration of Hα and Hβ of styryl group was established

from the corresponding coupling constant, $J_{H\alpha-H\beta} \approx 16$ Hz. The aromatic protons gave signals at various δ values depending on the nature and position of the substituent. Phenolic protons have appeared at δ 11.30-12.48 ppm. The methoxy protons gave a strong signal at 3.80 and methyl protons of the ester group at δ 2.08 ppm.

The ^{13}C-NMR values obtained at δ 107, 136 and 147 ppm, confirmed the presence of the pyrazole group. The high δ values at 160, 154, etc. confirmed that the aromatic carbons substituted with –OH, -OCH$_3$ groups, the values at δ 167-168 ppm reveals the presence of carbonyl group in methyl ester.

All the synthesized final products showed strong peaks in their LC-Mass spectra at respective mass values in positive ion and negative ion modes.

11. R^1 = NO$_2$, R^2 = 2,4-DNP   14. R^1 = Cl, R^2 = 2,4-DNP   17. R^1 = OCH$_3$, R^2 = 2,4-DNP
12. R^1 = NO$_2$, R^2 = Ph   15. R^1 = Cl, R^2 = Ph   18. R^1 = OCH$_3$, R^2 = Ph
13. R^1 = NO$_2$, R^2 = H   16. R^1 = Cl, R^2 = H   19. R^1 = OCH$_3$. R^2 = H

Scheme 1. *Reagents and Conditions:* (i) POCl$_3$, pyridine; rt. 4 hrs; (ii) KOH , dry pyridine, , rt. 1-2 hrs; (iii) R^2-NH-NH$_2$, MeOH, piperidine, 1hr stirring at rt.

Table 1. Optimization table

Entry	Solvent	Time (Min.)	Yield %
1	DCM + NaOH	80-90	80%
2	MeOH	90-120	75%
3	MeOH + piperidine	50-60	90%
4	MeOH + triethylamine	80-90	70%

Table 2. Substrate scope for synthesis of substituted pyrazoles

	Compound name	Yield (%)	M.P
1	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-nitrostyryl)-1-(2,4-dinitrophenyl)pyrazole (**11**)	0.65g (91.5%)	219- 220 $^{\circ}$C
2	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-nitrostyryl)-1-phenylpyrazole (**12**)	0.550 g. (93%)	231-232 $^{\circ}$C
3	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-nitrostyryl)-pyrazole (**13**)	0.360 g (91.1%)	246-247 $^{\circ}$C
4	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)-1-(2,4-dinitrophenyl)pyrazole (**14**)	0.300 g. (83%)	169-170 °C
5	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)-1-phenylpyrazole (**15**)	0.320 g. (88%)	89-90 °C
6	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)-pyrazole (**16**)	0.260 g. (86.6%)	223-224 $^{\circ}$C
7	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxy-styryl-1-(2,4-dinitrophenyl)pyrazole (**17**)	0.340 g. (94.4%)	186-187 °C
8	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxy-styryl)-1-phenylpyrazole (**18**)	0.350 g. (81%)	226-227 $^{\circ}$C
9	3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxy-styryl)pyrazole (**19**)	0.230 g. (76.6 %)	124-125 $^{\circ}$C

Biological testing data

All pyrazole derivatives except **12** exhibited thermal pain response much more effectively than Pentazocine in the same dose (Figure 1). This could be due to the pyrazole ring structure with the nature and position of substituents in the styryl group and at N(1) of pyrazole. All the compounds tested by Eddy's hot plate method showed better activity at the dosage of 30 mg/kg. The significant activity of all pyrazoles was due to the –Cl, – OMe at position 4 of the styryl group. In the absence of these groups, the compounds showed lower or non-significant activity, especially compound **12** has much lesser activity at 60 minutes, while **11**, **13**, and **15** have lesser activity at 30 minutes.

The synthesized pyrazoles exhibited significant anti-inflammatory activity when compared to the control group (Figure 2). The anti-inflammatory activities of compounds **11-19** were studied in the carrageenan-induced edema model of inflammation in mice. All the pyrazole derivatives showed significant anti-inflammatory activity. The compound **16, 17,** showed better activity might be due to the presence of methoxyl and chloro substituents at 4-position in the styryl ring of pyrazole. The compounds **11** and **12** exhibited good activity might well be due to the presence of the nitro group in the styryl ring. Hence, the

anti-inflammatory activity of pyrazole derivatives was increased with the styryl group substituted by an electron releasing group at position 4.

Tables S1 and S2 (Supplementary file) give full details of the analgesic and anti-inflammatory testing data of the individual compounds reported here. The results are summarized in Figures 1 and 2 below.



Figure 1. Graph for Analgesic activity.   **Figure 2.** Graph for Anti-inflammatory activity.

Conclusions

We have synthesized new pyrazole derivatives containing styryl groups at one position of pyrazole ring. The yield and purity of the final products were enhanced by using a trace amount of piperidine at the third stage of preparation. All reactions gave their target products in good to excellent yield. The reactions were rapid, facile and accomplished at room temperature. Almost all the synthesized compounds exhibited significant analgesic and anti-inflammatory activity against Pentazocine and Indomethacin *in vivo* of albino mice and rats respectively

Experimental Section

General: Melting points were measured by a Stuart Scientific melting point apparatus in open capillaries. NMR spectra were recorded on a Bruker spectrometer operating at 400 MHz for proton & 100 MHz for ^{13}C-spectra, using DMSO-d_6 as a solvent with TMS as an internal standard. Mass spectra were recorded on an Agilent-1100 period LC-MSD. Elemental analysis was performed using a EURO EA 3000 instrument. Acme silica gel-G and Merck silica gel (100 to 200, 60 to 120 meshes) were used for analytical TLC and column chromatography respectively. All other analytical grade chemicals and solvents were obtained from commercial sources and used as received.

The three ester compounds (**5-7**) were obtained by treating substituted 2-hydroxy-4-acetoxyacetophenones (1 mmol) with cinnamic acids (1.2 mmol) in pyridine solution (17. 8 mmol) in the presence of phosphorus oxychloride (3.0 mmol) as condensing agent according to the literature procedure.[34,35] All esters were converted into the respective β-hydroxy-enones (**8-10**) by stirring a pyridine (4.3 ml) solution of the ester (1.2 mmol) containing 250 mg of powdered potassium hydroxide for 2 hours following the method reported in the literature.[34,35]

The obtained β-hydroxy-enone (1mmol) and hydrazine (1mmol), were dissolved in MeOH (5 mL), and the resulting solution was stirred for about one hour at room temperature in the presence of a catalytic amount of piperidine. The completion of the reaction was monitored by TLC, and the reaction mixture was poured into ice-cold water containing 20% HCl. The solid thus obtained was filtered, washed, dried and purified by column chromatography over silica gel using hexane: EtOAc (4.75:0.25) as eluent. The resulting substituted pyrazole was recrystallized from a mixture of ethyl acetate and hexane.

3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-nitrostyryl)-1-(2,4-dinitrophenyl)pyrazole (**11**): Following the general procedure, **11** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-nitrophenyl)-3-hydroxypenta-2,4-dien-1-one (1 mmol, 0.5g,) and 2,4-dinitrophenylhydrazine (1mmol 0.198g), as a brown solid. Yield 0.65g (91.5%), mp 219-220 ^{o}C. ^{1}H-NMR (DMSO-d_6): δ 11.35 (1H, br, s, Ar-OH),8.88 (1H s),8.8 (1H, s) 7.77–7.71 (3H, d,), 8.369-8.352(3H,d),7.46 (1H, d, *J* = 16.0 Hz, H-α), 7.48 (1H, d, *J* = 16.0 Hz, H-β), 7.07 (1H, s, pyrazole), 7.106 (IH, d), 6.85 (1H,s), 2.O87 (s,3H Me).^{13}C NMR (DMSO-d_6): δ 167.34 (C=O), 157.55, 151.39, 147.09, 144.71, 144.65, 136.69, 130.07, 129. 74, 128.88 ,124.29, 123.05, 120.5, 118.47, 116.2, 115.94, 107.5, 100.6, 20.8(Me). LC-MS (ESI, negative ion mode): *m/z* 530 (M-H)$^{-}$. Anal**.** Calcd. (%) For C$_{25}$H$_{17}$N$_5$O$_9$: C, 56.49; H, 3.20; N, 13.18. Found (%): C, 56.51; H, 3.27; N, 13.17%.

3-(4-Acetoxy-2-hydroxy phenyl)-5-(4-nitrostyryl)-1-phenylpyrazole (**12**): Following the general procedure, **12** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-nitrophenyl)-3-hydroxypenta-2,4-dien-1-one (1 mmol, 0.5g) and phenylhydrazine (1 mmol, 0.144g), as light brown solid. Yield: 0.550g, (93%), mp 231-232 ^{o}C. ^{1}H-NMR (DMSO-d_6): δ 12.717 (1H, br, s, Ar OH), 8.07 (2H, d), 7.919 (1H, d, *J* = 16.0 Hz, H-α), 7.935 (1H, d, *J* = 16.0 Hz, H-β), 7.6-7.9 (5H, m), 7.7 (2H, d), 7.45 (1H, d),6.98 (1H, d) 6.904 (1H- s, pyrazole) 6.79 (1H ,s) 2.087 (3H, S). ^{13}C NMR (DMSO-d_6): δ 167.34 (C=O), 157.55, 151.39, 147.09, 144.71, 140.5, 136.69, 130.07, 129.74, 129.21, 128.88, 124.75, 124.15, 123.05, 120.5, 116.2, 115.94, 107.5, 100.6, 20.8 (Me). LC-MS (ESI, negative ion mode): *m/z* 440 (M-H)$^{-}$. Anal. Calcd. (%) for C$_{25}$H$_{19}$N$_3$O$_5$: C, 68.03; H, 4.31; N, 9.52. Found (%): C, 68.13; H, 4.57; N, 9.48.

3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-nitrostyryl)pyrazole (**13**): Following the general procedure, **13** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-nitrophenyl)-3-hydroxypenta-2,4-dien-1-one (0.33g), hydrazine sulfate (1 mmol, 0.130g), as light brownish colour solid. Yield-0.360g, (91.1%), mp 246-247^{0}C. ^{1}H-NMR (DMSO-d_6): δ 14.23 (NH, 1H, s), 12.717 (1H, br, s, Ar-OH), 8.301 (2H, d), 7.77 (1H, d, *J* = 16.0 Hz, H-α), 7.845 (1H, d, J = 16.0 Hz, H-β), 7.885 (1H, d), 7.7 (2H, d), 7.116 (1H, d), 6.8(1H, s), 6.7 (1H, s, pyrazole), 2.087 (3H, s). ^{13}C- NMR (DMSO-d_6): δ 167.34(C=O), 157.55, 151.39, 147.09, 144.71, 136.69, 130.07, 129.74, 128.88, 124.15, 123.05, 120.5, 116.2, 115.94, 107.5, 100.6, 20.8 (Me). LC-MS (ESI, positive ion mode): *m/z* 366 (M+H)$^{+}$. Anal. Calcd. (%) for C$_{19}$H$_{15}$N$_3$O$_5$: C, 62.4; H, 4.1; N, 11.5. Found (%): C, 62.39; H, 4.12; N, 11.48.

3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)-1-(2,4-dinitrophenyl)pyrazole (**14**): Following the general procedure, **14** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-chlorophenyl)-3-hydroxypenta-2,4-dien-1-one (1 mmol, 0.25g) and 2,4-dinitrophenylhydrazine (1mmol, 0.198 g), as a brownish orange solid. Yield 300 mg (83%), mp 169- 170 °C. ^{1}H-NMR (DMSO-d_6): δ 12.4 (1H, br, s, Ar-OH), 8.8 (1H, s),8.6 (1H, d),8.0 (1H, d),7.8(1H, d),7.7 (2H ,d),7.56 (1H, d, *J* = 16.0 Hz, H-α), 7.6 (1H, d, *J* = 16.0 Hz, H-β), 7.4 (2H, d),7.17 (1H, d), 7.15 (1H, s, pyrazole), 6.8 (1H, s),2.09 (3 H, s). ^{13}C-NMR (DMSO-d_6): δ 167.34(C=O), 157.55, 151.39, 147.07, 144.65, 136.6, 134.65 (Cl), 133.2, 129.2, 129.8, 128.8, 126.6, 126.3, 122.7, 120.5, 118.47, 115.94, 107.5, 103.4, 100.6, 20.8 (Me). LC-MS (ESI, positive ion mode): *m/z* 521.5 (M+H)$^{+}$. Anal. Calcd.(%) for C$_{25}$H$_{17}$ClN$_4$O$_7$: C, 57.64; H, 3.27; N, 10.7; Cl, 6.82. Found (%): C, 57.84; H, 3.25; N, 10.4.

3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)-1-phenylpyrazole (15): Following the general procedure, **15** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-chlorophenyl)-3-hydroxypenta-2,4-dien-1-one (1 mmol, 0.3g) and phenylhydrazine (1 mmol, 0.144g), as snuff-colored solid. Yield 320 mg, (88%), mp 89-90°C. ^{1}H-NMR (DMSO-d_6): δ 12.39 (1H, br, s, Ar-OH),7.93-7.89 (5H, m) ,7.7 (2H, d), 7.1-7.2 (2H, d,), 7.4 (2H, d),7.55 (1H, d, J = 6.0 Hz, H-α), 7.594 (1H, d, J = 16.0 Hz, H-β), 6.785 (1H, s, pyrazole), 6.8 (1H, s), 2.19 (3H, s, Me). ^{13}CNMR (DMSO-d_6): δ 167.3(C=O), 158.8, 153.2, 147.07, 142.3, 137.5, 134.65 (Cl), 133.2, 129.8, 129.2, 128.8, 126.3, 124.7, 122.7, 120.5, 114.6, 107.1, 100.6, 20.8 (Me). LC-MS (ESI, positive ion mode): m/z 431.5 (M+H) $^+$. Anal. Calcd. (%) for $C_{25}H_{19}ClN_2O_3$: C, 69.69; H, 4.41; N, 6.50. Found (%): C, 69.78; H, 4.70; N, 6.48%.

3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)pyrazole (16): Following the general procedure, **16** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-chlorophenyl)-3-hydroxypenta-2,4-dien-1-one (1mmol, 0.3 gm), hydrazine sulfate (1 mmol, 0.13 g), as light brownish solid. Yield 260 mg (86.6%), mp 223-224 °C. ^{1}H-NMR (DMSO-d_6): δ 14.23 (NH,1H, s), 12.4 (1H, br, s, Ar-OH),7.3 (1H, d), 7.7 (2H, d), 7.4 (2H, d), 7.27 (1H, d, J = 16.0 Hz, H-α), 7.63 (1H, d, J = 16.0 Hz, H-β), 7.1 (1H, d), 6.8 (1H, s), 6.54 (1H, s, pyrazole), 2.09 (3H, s). ^{13}C-NMR (DMSO-d_6): δ 167.34 (C=O), 157.55, 151.39, 147.09, 136.6, 134.65 (Cl), 133.2, 129.8, 129.21, 128.8, 126.3, 122.7, 120.5, 115.94, 107.5, 100.6, 20.8 (Me). LC-MS (ESI, negative ion mode): m/z- 353.5 (M-H)$^-$. Anal. Calcd (%). for $C_{19}H_{15}ClN_2O_3$: C, 64.3; H, 4.2; N, 7.8. Found (%): C, 64.4; H, 4.25; N, 7.48.

3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxystyryl-1-(2,4-dinitrophenyl)pyrazole (17): Following the general **17** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-methoxyphenyl)-3-hydroxypenta-2,4-dien-1-one (1 mmol, 0.3 gm) and 2,4-dinitrophenylhydrazine (1 mmol, 0.198 g), as brownish orange solid. Yield 340 mg (94.4%), mp 186-187 °C. ^{1}H-NMR (DMSO-d_6): δ 11.35 (1H, br, s, Ar-OH), 8.87 (1H, s), 8.84(1H, d), 7.8 (2H, d), 7.3 (1H, d, J = 16.0 Hz, H-α), 7.40 (1H, d, J = 16.0 Hz, H-β), 7.2 (2H, d), 7.14 (1H, d),7.0 (1H, s, pyrazole) 6.9 (2H, d), 6.8 (1H, s), 3.8 (3H, s, OCH$_3$), 2.08 (3H, s). ^{13}C-NMR (DMSO-d_6): δ 167.34 (C=O), 160.4, 157.5, 151.3, 147.07, 144.6, 136.6, 133.2, 128.9, 114.3, 128.8, 126.6, 126.3, 122.7, 120.5, 118.4, 115.9, 107.5, 103.4, 100.6, 55.5 (OCH$_3$) 20.8 (Me). LC-MS (ESI, Negative ion mode): m/z 515 (M-H)$^-$. Anal. Calcd.(%) for $C_{26}H_{20}N_4O_8$: C, 60.46; H, 3.87; N, 10.85. Found: C, 60.49; H, 3.39; N, 10.83%.

3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxystyryl)-1-phenylpyrazole (18): Following the general procedure **18** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-methoxyphenyl)-3-hydroxypenta-2,4- dien-1-one (1 mmol, 0.3 g) and phenylhydrazine (1 mmol, 0.144gm), as brownish yellow solid. Yield 350 mg, (81%), mp 226-227 °C. ^{1}H-NMR (DMSO-d_6): δ 11.35 (1H, br, s, Ar-OH), 7.5-7.8 (5H, m), 7.3 (1H, d, J = 16.0 Hz, H-α), 7.4 (1H, d, J = 16.0 Hz, H-β), 7.38 (1H, s),7.2 (2H, d), 7.1 (1H, d), 6.7 (1H, s, pyrazole) 6.9 (2H, d), 6.8 (1H d), 3.8 (3H, s, OCH3), 2.08 (3H, s). ^{13}C-NMR (DMSO-d_6): δ 167.34 (C=O), 160.4, 157.5, 151.3, 147.07, 142.3(C-N), 136.69, 133.2, 129.2, 128.9, 128.8, 127.5, 126.3, 124.7, 122.7, 120.5, 115.9, 114.3, 107.5, 100.6, 55.5(OCH$_3$) 20.8 (Me). LC-MS (ESI, positive ion mode): m/z 427 (M+H)$^+$.Anal. Calcd. (%) For $C_{26}H_{22}N_2O_4$: C, 73.24; H, 5.16; N, 6.57. Found: C, 73.30; H, 5.17; N, 6.48.

3-(4-Aceoxy-2-hydroxyphenyl)-5-(4-methoxystyryl)pyrazole (19): Following the general procedure, **19** was obtained from 1-(4-acetoxy-2-hydroxyphenyl)-5-(4-methoxyphenyl)-3-hydroxypenta-2,4-dien-1-one (1 mmol, 0.3 gm), hydrazine sulfate (1 mmol, 0.13gm) as light brownish solid. Yield 230 mg, (76.6 %), mp 124-125^{0}C. ^{1}H-NMR (DMSO-d_6): δ 11.35 (1H, br, s, Ar-OH), 7.5-7.8 (5H, m), 7.3 (1H, d, J = 16.0 Hz, H-α), 7.4 (1H, d, J = 16.0 Hz, H-β), 7.38 (1H, s),7.2 (2H, d), 7.1 (1H, d), 6.7 (1H, s, pyrazole) 6.9 (2H, d), 6.8 (1H d), 3.8 (3H, s, OCH3), 2.08 (3H, s). ^{13}C-NMR (DMSO-d_6): δ 167.3(CO), 160.4, 157.5, 151.3, 147.07, 136.69, 133.2, 128.9, 128.8, 126.3, 122.7, 120.5, 114.3, 115.9, 107.5, 100.6, 55.5(OCH$_3$), 20.8(Me). LC-MS (ESI, positive ion mode): m/z 351 (M+H)$^+$. Anal. Calcd. (%) For $C_{20}H_{18}N_2O_4$: C, 68.57; H, 5.14; N, 8. Found (%): C, 68.30; H, 5.15; N, 7.98.

Biological activity

Analgesic activity (Eddy's hot plate method)

The activity was studied by Eddy's hot plate method[37] in albino mice. The hot plate consists of an electrically heated surface with a controlled temperature of 55±1°C. Male albino mice of either sex with weight of about 26.5-47 gm. were placed on a hot plate and time of licking or jumping is recorded by stopwatch, before drug administration. The latency time is recorded after 0, 30, 60, 120 minutes following oral or subcutaneous administration of the test compound.

Male albino mice were selected and divided into eleven groups, containing three animals in each group. Weight matched animals were used in each group. These animals were fasted for twenty-four hours before the experiment. Animals of Group-I considered as control, were administered with 1% Acacia suspension. Animals of Group-II were treated with Pentazocine (standard drug, 30 mg/kg), which was considered as standard group. Animals of Group- III-XI were administered with the test sample and treated with different concentrations. The reaction time for each mouse was recorded at the time interval of 0, 30, 60 and 120 min after the administration of test substances by using Eddy's hot plate method. The % analgesic activity (PAA) was calculated by the following formula PAA = (T-C)/C × 100, C is the reaction time of the control and T is the reaction time of the test compound.

2 Anti-inflammatory Activity (carrageenan-induced rat paw edema)

The anti-inflammatory activity was carried out by carrageenan-induced paw edema test.[38] Wistar albino rats of either sex thirty-three animals (122-140 g.) were divided into eleven groups, each with three animals. The animals of group-I considered as control, were administered with normal saline. The animals of group-II are treated with standard drug indomethacin (20 mg/kg). Animals of Group-III-XI were administered with the test sample. Test compounds and standard drug indomethacin (10 mg/kg) were suspended in 0.5% w/v of sodium carboxyl methylcellulose (CMC), which was used as a vehicle for the control group.

The rats were dosed with test drugs orally, including the reference standard with the help of an oral feeding needle. After 30 minutes of drug administration, 0.1 mL of 1% w/v carrageenan solution in saline was injected in the sub plantar region of the left hind paw of control as well as standard and test groups. The increased volume of paw edema (in mL) was determined immediately after the injection of carrageenan and 30, 60 & 120 minutes later. The difference between 30 and 60 minutes was taken as edema volume. The % inhibition of anti-inflammatory activity (PAA) was calculated by the following formula PAA = (C-T)/C × 100, C is the reaction time of the control and T is the reaction time of the test compound. Data were expressed as means ± SEM.

Acknowledgments

Supplementary Material

The NMR spectra of some synthetic compounds, and tabulated details of the analgesic and anti-inflammatory testing data, are given in the Supplementary file linked to this article.

References

1. Kleeman, A.; Engel, J.; Kutscher, B.; Reichert, D. *Pharmaceutical Substances*, 3rd Ed.; George Thieme: Stuttgart, New York, NY, **1999**, 1190.
2. Theodoridis, G.; In *Modern Crop Protection Compounds*; Kramer, W.; Schirmer, U., Eds.; Wiley-VCH: Weinheim, **2007,** 153.
3. Vicentini, C. B.; Romagnoli, C.; Andreotti, E.; Mares, D. J. *Agr. Food Chem*. **2007**, *55*, 10331.
   https://doi.org/10.1021/jf072077d
4. Eicher, T.; Hauptmann, S., Edition IInd, *The Chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications*, Wiley-VCH:Monheim,2003. ISBN 3527307206.
   https://doi.org/10.1002/352760183X
5. Krygowski, T. M.; Anulewicz, R.; Cyrafiski, M. K.; Puchala, A.; Rasata, D. *Tetrahedron* **1998**, *54*, 12295.
   https://doi.org/10.1016/S0040-4020(98)00749-2
6. Knorr, L. *Ber. Deut. Chem. Ges*. **1883**, *16*, 2597.
   https://doi.org/10.1002/cber.188301602194
7. Polshettiwar, V.; Varma, R. S. *Tetrahedron Lett*. **2008**, *49*, 397.
   https://doi.org/10.1016/j.tetlet.2007.11.017
8. Arrieta, A.; Carrillo, J. R.; Cossiò, F. P.; Ortiz, A. D.; Gomez-Escalonilla, M.J. ; de la Hoz, A. ; Langa, F . ; Moreno, A. *Tetrahedron* **1998**, *54*, 13167.
   https://doi.org/10.1016/S0040-4020(98)00798-4
9. Remy, R. J.; Secrist III, J. A. *Nucleosides Nucleotides* **1985**, *4*, 411.
   https://doi.org/10.1080/07328318508056172
10. Sachchar S. P.; Singh A. K. *Int. J. Comp. Socio*. **1985**, *12,* 142.
11. Nada, M. A.; Hamdi, M. H.; Ahmed, S. M.; Omar, A. M. *J. Bio. Chem*. **2009,** *20*, 975.
12. Pattan, S. R. *Ind. J. Chem.* **2009**, *48,* 1453.
13. Mathew, B.; Suresh, J.; Anbazhagan, S. *Amer. J. Chem. Soc.* **2012**, *2(3),* 1.
14. Kumar, A. S.; Ilango, K.; Manikandan, R. S.; Ramalakshmi, N. *Eur. J. Chem.* **2009**, *6,* 123.
   https://doi.org/10.1155/2009/128586
15. Sahu, S. K.; Banerjee, M.; Samantray, A.; Behera, C.; Azam, M. A. *Tropical J. Pharm. Res.* **2008**, *7,* 961.
   https://doi.org/10.4314/tjpr.v7i2.14664
16. Panneer, S. T.; Saravanan, G.; Prakash, C. P.; Kumar, P. D. *African J. Chem.* **2011**, *1,* 126.
17. Mohareb, R. M.; El-Sayed, N. N.; Abdelaziz, M. A. *Molecules* **2012**, *17,* 8449.
   https://doi.org/10.3390/molecules17078449
18. El-Sayed, W. A.; Flefel, E. M.; Morsy, M. H. *Der Pharm. Chem.* **2012**, *4,* 23.
19. Bole, S. B.; Nargund, L. V.; Nargund, R.; Devaraju, K. S.; Vedamurthy, A. *Int. J. Pharm. Sci.* **2011**, *3,* 161.
20. Tarun, S.; Mithilesh, Raju, S.; Pooja, C.; Saraf, S. K. *Int. J. Res. Pharm. Sci.* **2012**, *2,* 81.
21. Olofson, R. A.; and Kendall, R. V. J. *J. Org. Chem.* **1970**, *35*, 2246.

https://doi.org/10.1021/jo00832a031

22. Lidström, P.; Tierney, J.; Wathey B.; and Westman, J. *Tetrahedron* **2001,** *57*, 9225.
https://doi.org/10.1016/S0040-4020(01)00906-1

23. *Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry: toward Heterocycles and Natural Products*, Padwa, A.; Pearson W. H., Eds. Wiley:Hoboken, 2003; p 681.

24. Fustero, S.; Sanchez-Rosell, M.; Barrio, P.; Simn-Fuentes, A. *Chem. Rev*. **2011**, *111*, 6984
https://doi.org/10.1021/cr2000459

25. Babinski, D. J.; Aguilar, H. R.; Still, R.; Frantz, D. E. *J. Org. Chem*. **2011**, *76,* 5915.
https://doi.org/10.1021/jo201042c

26. Simovic, D. M. D., Marks, V.; Chatfield, D. C.; Rein, K. S. *J. Org. Chem*. **2006**, *71,* 650.

27. Kumar, R.; Verma, D.; Mobin, S. M.; Namboothiri, I. N. N. *Org. Lett*. **2012**, *14,* 4070.
https://doi.org/10.1021/ol301695e

28. Foster, R. S.; Jakobi H.; Harrity, J. P. A. *Org. Lett.* **2012**, *14,* 4858.
https://doi.org/10.1021/ol3021918

29. Gioiello, A.; Khamidullina, A.; Fulco, M. C.; Venturoni, F.; Zlotsky, S.; Pellicciari, R. *Tetrahedron Lett*. **2009**, *50*, 5978.
https://doi.org/10.1016/j.tetlet.2009.07.152

30. Kumar, R.; Namboothiri, I. N. N. *Org. Lett.* **2011**, *13*, 4016.
https://doi.org/10.1021/ol201534f

31. Ichikawa, H.; Watanabe, R.; Fujino, Y.; Usami, Y. *Tetrahedron Lett.* **2011**, *52*, 4448.
https://doi.org/10.1016/j.tetlet.2011.06.061

32. Browne, D. L.; Vivat, J. F.; Plant, A.; Gomez Bengoa, E.; Harrity, J. P. A. *J. Am. Chem. Soc.* **2009**, *131*, 7762.
https://doi.org/10.1021/ja902460n

33. Furniss, B. S.; Hannaford, A. J.; Rogers, V.; Smith, P. W. G.; Tatchell, A. R. in *Vogel's Textbook of Practical Organic Chemistry*, ELBS:UK, 4th Edn, 1978, p802.

34. Madhava Rao, V.; Sudhakar, D.; Siddhaiah, V.; Venkatarao, C. *Int. J. Synth. Characterisation* **2008**, *1,* 17.

35. Priyadarsini, P.; Ujwalaa, B.; VenkataRao, C.; MadhavaRao, V. *Der Pharmacia Lettre* **2012**, *4*, 1123.

36. Pinto, D. C.G.A. ; Silva, A.M.S. ; Cavaleiro, J.A.S. *Tetrahedran 1999, 55, 10187.*
https://doi.org/10.1021/ja902460n

37. Verma, A. K.; Martin, A. Singh A. K. *Asian J. Biomed. Pharm. Sci.* **201**4, *4 (37)*, 21.
https://doi.org/10.1007/s40009-013-0192-5

38. Dhingra, A. K.; Chopra, B.; Dass, R.; and Mittal, S .K. *Int. J. Med. Chem.* **2016**, *1.*